Improving Characterization of Calcifications With Contrast-Enhanced Mammography
NCT ID: NCT03639129
Last Updated: 2019-05-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2019-05-31
2021-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Can Contrast-Enhanced Spectral Mammography Improve the Accuracy of a Diagnosis
NCT03929822
Contrast-Enhanced Mammography for the Evaluation of Mammographic Microcalcifications
NCT05046301
Tomosynthesis vs. Contrast-Enhanced Mammography in Women With Personal History of Breast Cancer in Western Pennsylvania
NCT04085510
Comparing Breast Magnetic Resonance Imaging (MRI) and Contrast-enhanced Mammography (CEM)
NCT06008301
Contrast Enhanced Mammography in Diagnosing Patients With Suspicious Breast Findings
NCT03929783
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Contrast-enhanced mammography (CME)
-Patients who meet eligibility criteria and consent to participate in this study will complete a CEM examination prior to or on the day that biopsy is scheduled. CEM must occur no later than 60 days after the diagnostic mammogram. The standard of care biopsy must occur no later than 30 days after CEM.
Contrast-enhanced mammography
Contrast-enhanced mammography was FDA approved in 2012 and is currently being used in both clinical and research settings at breast imaging centers throughout the world
Biopsy
Standard of care
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Contrast-enhanced mammography
Contrast-enhanced mammography was FDA approved in 2012 and is currently being used in both clinical and research settings at breast imaging centers throughout the world
Biopsy
Standard of care
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 30 years of age.
* Able to understand and willing to sign an IRB-approved written informed consent document
* GFR ≥ 30 mL/min/1.73 m2
Exclusion Criteria
* Prior history of allergy or hypersensitivity reaction to iodinated contrast
* History of chronic renal disease (including dialysis, kidney transplant, single kidney, renal cancer, or renal surgery)
* Patients with known thyroid disorders, pheochromocytoma or sickle cell anemia
30 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Washington University School of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Matthew Covington, M.D.
Role: PRINCIPAL_INVESTIGATOR
Washington University School of Medicine
Related Links
Access external resources that provide additional context or updates about the study.
Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
201709088
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.